[Considerations on projected pharmacology of antiparkinson agents].
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D004285:Dogs; D004336:Drug Antagonism; D006168:Guinea Pigs; D008297:Male; D009966:Orphenadrine / Q000494:pharmacology; D010276:Parasympatholytics; D010300:Parkinson Disease / Q000188:drug therapy*; D010830:Physostigmine / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D014282:Trihexyphenidyl / Q000494:pharmacology
D010276:Parasympatholytics; D011759:Pyrrolidines; D014282:Trihexyphenidyl; D001285:Atropine; D010830:Physostigmine; D009966:Orphenadrine
Réflexions sur la pharmacologie prévisionnelle des antiparkinsoniens.